Home / Market News / $APYX

$APYX news and market catalysts

The 6 most recent market catalysts affecting $APYX, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.

6 catalysts 2 high impact 2 bullish 2 bearish Medical Devices
Nov 5, 2026 Corporate Catalyst Bullish Impact 80
Apyx Medical Corporation Reports Third Quarter 2026 Financial Results
Apyx Medical Corporation announced its third-quarter 2026 financial results, showing a 9% year-over-year increase in total revenue to $14.0 million. This growth was primarily fuele…
Oct 23, 2026 Corporate Catalyst Bearish Impact 60
Purcell & Lefkowitz LLP Announces Shareholder Investigation of Apyx Medical Corporation
This 8-K filing discloses that a law firm, Purcell & Lefkowitz LLP, has initiated an investigation into Apyx Medical Corporation's directors for alleged breaches of fiduciary duty.…
Oct 22, 2026 Corporate Catalyst Neutral Impact 55
Apyx Medical Corporation to Release Third Quarter of Fiscal Year 2026 Financial Results on November 5, 2026
This 8-K filing is a standard pre-earnings announcement from Apyx Medical Corporation, informing the market that its Q3 2026 financial results will be released on November 5, 2026.…
Aug 6, 2026 Corporate Catalyst Bullish Impact 92
Apyx Medical Q2 EPS $(0.07) Beats $(0.08) Estimate, Sales $13.884M Beat $13.175M Estimate
Apyx Medical's Q2 earnings report shows a beat on both EPS and sales estimates. The company reported a smaller loss per share than anticipated and significantly higher sales, indic…
Aug 6, 2026 Corporate Catalyst Bearish Impact 55
Apyx Medical Affirms FY2026 Sales Guidance of $59.000M-$60.000M vs $59.554M Est
Apyx Medical's 8-K filing indicates that the company is reaffirming its sales guidance for fiscal year 2026, keeping the range at $59.000 million to $60.000 million. This is a non-…
Jul 13, 2026 Corporate Catalyst Neutral Impact 65
HC Wainwright & Co. Initiates Coverage On Apyx Medical with Buy Rating, Announces Price Target of $7
HC Wainwright & Co. analyst Yi Chen initiated coverage on Apyx Medical (APYX) with a 'Buy' rating and set a price target of $7. This event is significant for APYX as new analyst co…
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.